Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798802 | PMC |
| http://dx.doi.org/10.21037/tcr.2019.06.43 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clofazimine enhances anti-glioma effect of immunotherapy.
Int Immunopharmacol
January 2025
Medical Complex, School of Medicine & Life Science, Far Eastern Federal University, Vladivostok, Russian Federation 690091. Electronic address:
Rationale: Glioblastoma is one of the most aggressive human brain tumors. The prognosis is unfavorable and treatment effects are relatively low. However, temozolomide (TMZ) chemotherapy may prolong patients' survival.
View Article and Find Full Text PDFProtein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials.
Pharmacol Res
January 2025
Department of Systems Medicine, University of Rome Tor Vergata, Rome 00133, Italy.
Glioblastoma (GBM) is the most common and lethal primary brain tumor. The standard treatment for newly diagnosed GBM includes surgical resection, when feasible, followed by radiotherapy and temozolomide-based chemotherapy. Upon disease progression, the anti-vascular endothelial growth factor-A (VEGF-A) monoclonal antibody bevacizumab, can be considered.
View Article and Find Full Text PDFTumor Treating Fields (TTFields) Therapy and Lomustine Chemotherapy for the Treatment of Unresectable Progressive Glioblastoma.
Case Rep Oncol
September 2024
Department of Radiology, MVZ am Klinikum Rosenheim, Rosenheim, Germany.
Introduction: Tumor Treating Fields (TTFields) therapy used concomitantly with maintenance temozolomide through second progression after radio-chemotherapy is associated with improved survival outcomes compared to adjuvant temozolomide alone in individuals with newly diagnosed glioblastoma (GBM). Lomustine (CCNU) is frequently used as monotherapy or concomitant with other chemotherapy regimens as second-line treatment for recurrent GBM.
Case Presentation: We report a 59-year-old female patient diagnosed with -promoter methylated, isocitrate dehydrogenase-wildtype GBM (World Health Organization Grade 4) who received TTFields therapy concomitant with first- and second-line chemotherapy following partial resection.
The Role of Systemic Therapies in the Treatment of Grades 1-4 Gliomas.
Cureus
September 2024
Medical Physics, Greater Poland Cancer Centre, Poznań, POL.
The primary treatment for gliomas typically involves tumor resection followed by adjuvant radiotherapy, with increasing emphasis on chemotherapy and molecularly targeted drugs. This study aimed to review and summarize the literature on the systemic therapy of malignant gliomas. Chemotherapy may be considered in grades 2 and 3 gliomas, especially when mutations in 1p19q-codeletion are detected.
View Article and Find Full Text PDFImpact of upfront adjuvant chemoradiation on survival in patients with molecularly defined oligodendroglioma: the benefits of PCV over TMZ.
J Neurooncol
January 2025
Department of Neurosurgery, Johns Hopkins University School of Medicine, Phipps Building, Room 118, 600 N. Wolfe Street, Baltimore, MD, 21287, USA.
Article Synopsis
- Oligodendroglioma is a brain tumor characterized by specific genetic mutations and treatments typically involve surgery followed by either observational care or a combination of radiation and chemotherapy.
- This study analyzed data from 277 patients with IDH-mutant, 1p/19q codeleted oligodendrogliomas to examine the impact of different adjuvant treatment regimens on progression-free survival (PFS).
- Results indicated that patients with grade 3 tumors showed significantly longer PFS when treated with radiation and PCV chemotherapy compared to those receiving radiation with TMZ or no adjuvant therapy, emphasizing the need for more research in this area.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!